

Michael Willis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5537673/publications.pdf>

Version: 2024-02-01

24
papers

606
citations

687363

13
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

599
citing authors

#	ARTICLE	IF	CITATIONS
1	The public economic burden of sub-optimal type 2 diabetes control on tax payors in Sweden: Looking beyond health costs. <i>Diabetes, Obesity and Metabolism</i> , 2022, , .	4.4	2
2	Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting. <i>Applied Health Economics and Health Policy</i> , 2022, , 1.	2.1	1
3	Cost-Effectiveness of Canagliflozin Added to Standard of Care for Treating Diabetic Kidney Disease (DKD) in Patients with Type 2 Diabetes Mellitus (T2DM) in England: Estimates Using the CREDEM-DKD Model. <i>Diabetes Therapy</i> , 2021, 12, 313-328.	2.5	21
4	Macrovascular Risk Equations Based on the CANVAS Program. <i>Pharmacoeconomics</i> , 2021, 39, 447-461.	3.3	4
5	Swedish guidelines for device-aided therapies in Parkinson's disease – Economic evaluation and implementation. <i>Acta Neurologica Scandinavica</i> , 2021, 144, 170-178.	2.1	7
6	Health economic modelling of diabetic kidney disease in patients with type 2 diabetes treated with Canagliflozin in Belgium. <i>Acta Clinica Belgica</i> , 2021, , 1-10.	1.2	1
7	Development and Internal Validation of a Discrete Event Simulation Model of Diabetic Kidney Disease Using CREDESCENCE Trial Data. <i>Diabetes Therapy</i> , 2020, 11, 2657-2676.	2.5	8
8	Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. <i>Pharmacoeconomics</i> , 2020, 38, 953-969.	3.3	16
9	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. <i>Pharmacoeconomics</i> , 2019, 37, 1305-1312.	3.3	28
10	Challenges and Opportunities Associated with Incorporating New Evidence of Drug-Mediated Cardioprotection in the Economic Modeling of Type 2 Diabetes: A Literature Review. <i>Diabetes Therapy</i> , 2019, 10, 1753-1769.	2.5	11
11	Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 222-233.	2.8	2
12	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. <i>Value in Health Regional Issues</i> , 2019, 18, 65-73.	1.2	3
13	Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. <i>Diabetes Therapy</i> , 2018, 9, 565-581.	2.5	13
14	Multivariate Prediction Equations for HbA 1c Lowering, Weight Change, and Hypoglycemic Events Associated with Insulin Rescue Medication in Type 2 Diabetes Mellitus: Informing Economic Modeling. <i>Value in Health</i> , 2017, 20, 357-371.	0.3	23
15	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). <i>Pharmacoeconomics</i> , 2017, 35, 375-396.	3.3	24
16	Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2016, 23, e151-68.	1.4	8
17	Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. <i>Value in Health Regional Issues</i> , 2015, 8, 8-19.	1.2	17
18	Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations. <i>PLoS ONE</i> , 2014, 9, e110235.	2.5	34

#	ARTICLE	IF	CITATIONS
19	Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). <i>Journal of Medical Economics</i> , 2013, 16, 1007-1021.	2.1	27
20	Hospitalisation Utilisation and Costs in Schizophrenia Patients in Finland before and after Initiation of Risperidone Long-Acting Injection. <i>Schizophrenia Research and Treatment</i> , 2012, 2012, 1-9.	1.5	14
21	The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden. <i>European Journal of Health Economics</i> , 2010, 11, 585-594.	2.8	32
22	Reducing Uncertainty in Value-Based Pricing Using Evidence Development Agreements. <i>Applied Health Economics and Health Policy</i> , 2010, 8, 377-386.	2.1	42
23	A Cost-Effectiveness Model of Tibolone as Treatment for the Prevention of Osteoporotic Fractures in Postmenopausal Women in Sweden. <i>Clinical Drug Investigation</i> , 2001, 21, 115-127.	2.2	11
24	The Emergence of Crack Cocaine and the Rise in Urban Crime Rates. <i>Review of Economics and Statistics</i> , 2000, 82, 519-529.	4.3	142